Silexion Therapeutics Reports Groundbreaking Positive Initial Data from Systemic Administration of SIL204 in Orthotopic Pancreatic Cancer Models
Provided By GlobeNewswire
Last update: Mar 5, 2025
Grand Cayman, Cayman Islands, March 05, 2025 (GLOBE NEWSWIRE) -- Silexion Therapeutics Corp. (NASDAQ: SLXN) ("Silexion" or the "Company"), a clinical-stage biotechnology company pioneering RNA interference (RNAi) therapies for KRAS-driven cancers, today announced positive data from orthotopic pancreatic cancer models demonstrating that subcutaneously administered SIL204 effectively reduces both primary tumor growth and metastatic spread.
Read more at globenewswire.com0.9215
-0.03 (-2.99%)
Find more stocks in the Stock Screener
SLXN Latest News and Analysis
4 days ago - ChartmillThese stocks that are showing activity before the opening bell on Monday.The US market session of Monday has yet to be opened, let's have a look at the top gainers and losers in the pre-market session today.
6 days ago - ChartmillFriday's after hours session: top gainers and losersWondering what's happening in today's after-hours session? Stay tuned for the latest updates on stock movements.
10 days ago - ChartmillThese stocks are moving in today's after hours sessionLet's have a look at what is happening on the US markets after the closing bell on Monday. Below you can find the top gainers and losers in today's after hours session.
